Editor’s Note: The U.S. Transhumanist Party’s Biotechnology Advisor, Dr. Bill Andrews, provides information regarding an innovative effort to fund his longevity research via the new Telomere Coin cryptocurrency. Dr. Andrews has long pursued the goal of lengthening human telomeres and reversing biological aging. The U.S. Transhumanist Party will provide more information regarding the Telomere Coin as it becomes available. The above video was created by the defytime Group. To find out more about defytime and the Telomere Coin, read the whitepaper here. The U.S. Transhumanist Party considers the Telomere Coin to be an Allied Project and looks forward to the results of this innovative approach in raising much-needed funds for the work of Dr. Andrews.
~ Gennady Stolyarov II, Chairman, United States Transhumanist Party, May 8, 2018
Message from Dr. Bill Andrews: The Telomere Coin could be the best opportunity ever to get funding for my research. The Initial Coin Offering (ICO) hasn’t started yet but will in July. But, now there is a pre-sale of the coin underway for investors to buy coins at a lower price. To buy the coins go to http://defytime.groupand click “Go to ICO” and then click on “Join Pre-Sale”.
New Clinical Study May Be the World’s First Cure for Alzheimer’s Disease – Press Release from Libella Gene Therapeutics
ORLANDO, Fla., Jan. 10, 2018 /PRNewswire/ — Libella Gene Therapeutics LLC will conduct an OUS (outside the United States) clinical trial in Cartagena, Colombia, using gene therapy to reverse age-related diseases, starting with Alzheimer’s. Unlike traditional drugs, which tend to be taken for months or years at a time, gene therapy interventions are intended to be one-off treatments that tackle a disease at its source, repairing faulty DNA and allowing the body to fix itself.
Every day 228 Americans die from Alzheimer’s disease, and there is currently no known treatment or cure. Gene therapy offers the ability to permanently correct a disease at its most basic level, the genome, and could offer cures for many conditions that are currently considered incurable. According to Dr. Bill Andrews, the scientist leading the study, “Human telomerase reverse transcriptase (hTERT) is an enzyme whose expression plays a role in cellular aging and is normally repressed in cells, resulting in progressive shortening of telomeres. Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer.”
By inducing telomerase, Dr. Andrews and Libella Gene Therapeutics hope to lengthen telomeres in the body’s cells. The clinical trial will treat a limited number of patients using the gene therapy treatment, which has been demonstrated as safe, with minimal adverse reactions in over 186 clinical trials.
Dr. Andrews has been featured in Popular Science, on the “Today” show and in numerous documentaries on the topic of life extension. As one of the principal discoverers of both the RNA and protein components of human telomerase, Dr. Andrews was awarded second place as “National Inventor of the Year” in 1997. He earned a Ph.D. in molecular and population genetics at the University of Georgia in 1981. He has served in multiple senior science and technology roles at leading bioscience corporations. Dr. Andrews is a named inventor on over 50 U.S.-issued patents on telomerase and is the author of numerous scientific research studies published in peer-reviewed scientific journals.
On why the company decided to conduct its clinical research project outside the United States, Libella Gene Therapeutics president Dr. Jeff Mathis said, “Traditional clinical trials in the U.S. can take years and millions — or even billions — of dollars. The research and techniques that have been proven to work are ready now. We believe we have the scientist, the technology, the physicians, and the lab partners that are necessary to get this trial done faster in Colombia.”
The clinical trial is prepping to begin in the first quarter of 2018 and will be conducted at MediHelp Services Clinic in beautiful and tourist-friendly Cartagena, Colombia. The state-of-the-art facility has hosted international public figures including athletes, celebrities and politicians. Dr. Javier Hernandez, MediHelp’s medical director, will oversee the trial.
Colombia’s clinical research regulation is friendly to gene therapy trials, with one of the fastest approval times in Latin America for this kind of research. The trial’s clinical study design; regulatory, operation and logistical support; project management; statistical analysis; and study monitoring services will be provided by LATAM Market Access Inc., a Florida-based clinical research company.
About Libella Gene Therapeutics LLC With a mission to reverse aging and cure all age-related diseases, starting with Alzheimer’s, Libella Gene Therapeutics has exclusively licensed the AAV Reverse (hTERT) transcriptase enzyme technology from Sierra Sciences and Dr. Bill Andrews. More information at www.libellagenetherapeutics.com.
About LATAM Market Access Inc. Dedicated to helping innovative life science companies gather cost-effective clinical data at leading research institutions, the company provides clinical study design; regulatory, operational and logistics support; project management; statistical analysis; and study monitoring services. More information at www.latammarketaccess.com.
Second Enlightenment Salon – Gennady Stolyarov II, Bill Andrews, Bobby Ridge, and Scott Jurgens Discuss the Convergence of Technological Advances
U.S. Transhumanist Party Chairman Gennady Stolyarov II invited Dr. Bill Andrews (the U.S. Transhumanist Party’s Biotechnology Advisor), Bobby Ridge (the U.S. Transhumanist Party’s Secretary-Treasurer), and Scott Jurgens to his Second Enlightenment Salon, where they shared their thoughts on emerging life-extension research, advances in prosthetics and orthotics, philosophy of science, brain-computer interfaces, and how technologies from a variety of fields are converging to bring about a paradigm shift in the human condition – hopefully within the coming decades.
U.S. Transhumanist Party Discussion Panel on Life Extension – February 18, 2017
For its second expert panel, the U.S. Transhumanist Party invited Bill Andrews, Aubrey de Grey, Ira Pastor, and Ilia Stambler to discuss life extension and the quest to reverse biological aging through science and technology.
This two-hour panel discussion, moderated by Chairman Gennady Stolyarov II, took place on Saturday, February 18, 2017, at 10 a.m. U.S. Pacific Time. In this interactive venue, many opportunities for fresh discourse arose on the possibility of achieving dramatically greater longevity within our lifetimes. The substance of the discussion begins at 4:25 in the recording.
Questions the panelists considered include the following:
(i) How would you characterize the current state of efforts to reverse senescence / lengthen human lifespans? (ii) How does progress in the areas of research you have delved into compare to your expectations approximately 10 to 15 years ago? (iii) What are the most significant challenges and obstacles that you perceive to exist in the way of achieving serious reversal of biological aging? (iv) What key technologies and methods of delivering treatments to patients would need to be developed in order for longevity escape velocity to be affordably achieved society-wide? (v) What political reforms and societal / attitudinal changes would you advocate to accelerate the arrival of effective treatments to reverse biological aging and lengthen lifespans? (vi) Are you concerned about any current political trends and how they might affect the progress of research into combating biological aging? (vii) What can laypersons who are sympathetic to your goals do in order to hasten their realization? How can the effort to defeat aging become as popular and widely supported as efforts to defeat cancer and ALS are today? (viii) What lessons can the history of anti-aging research offer to those who seek to advocate and help achieve effective scientific breakthroughs in this area in the coming years and decades?
Dr. Bill Andrews is the President and CEO of Sierra Sciences – http://www.sierrasci.com/. As a scientist, athlete, and executive, he continually pushes the envelope and challenges convention. In his 35-year biotech career, he has focused the last 23 years on finding ways to extend the human lifespan and healthspan through telomere maintenance. As one of the principal discoverers of both the RNA and protein components of human telomerase, Dr. Andrews was awarded 2nd place as “National Inventor of the Year” in 1997.
Dr. Aubrey de Grey is the biomedical gerontologist who researched the idea for and founded SENS Research Foundation – http://www.sens.org/. He received his BA in Computer Science and Ph.D. in Biology from the University of Cambridge in 1985 and 2000, respectively. Dr. de Grey is Editor-in-Chief of Rejuvenation Research, is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organizations.
Ira Pastor has 30 years of experience across multiple sectors of the pharmaceutical industry, including pharmaceutical commercialization, biotech drug development, managed care, distribution, OTC, and retail. He is the CEO of BioQuark, Inc. – http://www.bioquark.com/ – and Executive Chairman of ReAnima Advanced Biosciences – https://reanima.tech/.
Dr. Ilia Stambler is a researcher at Bar Ilan University, Israel. His research focuses on the historical and social implications of aging and life-extension research. He is the author of A History of Life-extensionism in the Twentieth Century – www.longevityhistory.com. He is actively involved in advocacy for aging and longevity research – www.longevityforall.org.